טוען...
Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma
BACKGROUND: Vemurafenib, an inhibitor of genetically activated BRAF, is now commonly prescribed for metastatic melanoma harboring a BRAF mutation. Reports on side effects have focused on cutaneous complications. We here present a case of a severe pan-uveitis associated with vemurafenib use. CASE PRE...
שמור ב:
| הוצא לאור ב: | BMC Cancer |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2013
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4219461/ https://ncbi.nlm.nih.gov/pubmed/24289205 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-13-561 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|